GliaPharm SA
Targeting Glial Cells and Brain Metabolism to Treat Neurological Diseases
Targeting Glial Cells and Brain Metabolism to Treat Neurological Diseases
GliaPharm is a Swiss-based biotechnology company founded in 2016, specializing in the development of treatments for neurological and psychiatric disorders. The company's slogan "Targeting Glial Cells and Brain Metabolism to Treat Neurological Diseases" encapsulates its innovative approach.
GliaPharm focuses on targeting glial cells, which are the 'support cells' of neurons, to sustain and enhance brain metabolism in pathological conditions. With a vision to become a leading biotechnology company, it places emphasis on glia-mediated pathways as agents for neuroprotection and maintenance of cognitive functions.
The company's recent milestone includes securing $4.20M in grant investment on 15 December 2023, with the Alzheimer's Drug Discovery Foundation being the noteworthy investor. Operating within the biotechnology and health care industries, GliaPharm's headquarters are based in Switzerland.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $4.20M | 1 | Alzheimer's Drug Discovery Foundation | 15 Dec 2023 |
| Debt Financing | Fr.100.00K | 1 | FONGIT Innovation Fund | 04 Jul 2022 |
| Seed Round | Fr.2.00M | 1 | Gliaven | 26 May 2020 |
| Non Equity Assistance | Unknown | 1 |
|
23 May 2017 |
No recent news or press coverage available for GliaPharm SA.
We care about your data, and we'd love to use cookies make your experience better.
